The goal of researchers working in the area of developmental toxicology is to prevent adverse reproductive outcomes (early pregnancy loss, birth defects, reduced birth weight, and altered functional development) in humans due to exposures to environmental contaminants, therapeutic drugs, and other factors. To best achieve that goal, it is important that relevant information be gathered and assimilated in the risk assessment process. One of the major challenges of improved risk assessment is to better use all pertinent biological and mechanistic information. This may be done qualitatively (e.g., demonstrating that the experimental model is not appropriate for extrapolation purposes); semiquantitatively (using information to reduce the degree of uncertainty present under default extrapolation procedures), or quantitatively (formally describing the relationships between exposure and adverse outcome in mathematical forms, including components that directly reflect individual steps in the overall progression of toxicity). In this paper we review the recent advances in the risk assessment process for developmental toxicants and hypothesize on future directions that may revolutionize our thinking in this area. The road to these changes sometimes appears to be a well-mapped course on a relatively smooth surface; at other times the path is bumpy and obscure, while at still other times it is only a wish in the eye of the engineer to cross an uncharted and rugged environment.
During the last 5 years, significant changes in the risk assessment process for noncancer health effects of environmental contaminants have begun to appear. The first of these changes is the development and use of statistically based dose-response models (the benchmark dose approach) that better utilize data derived from existing testing approaches. Accompanying this change is the greater emphasis on understanding and using mechanistic information to yield more accurate, reliable, and less uncertain risk assessments. The next stage in the evolution of risk assessment will be the use of biologically based dose-response (BBDR) models to build factors related to the underlying kinetic, biochemical, or physiological processes, which may be perturbed by a toxicant, into the statistically based models. Such models are now emerging from several research laboratories. The introduction of quantitative models and the incorporation of biological information into them has pointed to the need for even more sophisticated modifications, which we term embryologically based dose-response (EBDR) models. Because these models are based upon the understanding of normal morphogenesis, they represent a quantum leap in our thinking, but their complexity presents daunting challenges both to the developmental biologist and the developmental toxicologist. However, the remarkable progress in the understanding of mammalian embryonic development at the molecular level that has occurred over the last decade should eventually enable these as yet hypothetical models to be brought into use.
A firm understanding of the mechanisms of normal development is required to adequately characterize mechanisms of abnormal development. Indeed, the paucity of complete descriptions of mechanisms of chemically induced dysmorphogenesis is in large part based on our poor understanding of normal developmental processes. For example, without an understanding of the forces that control the outgrowth and differentiation of the limb bud, how can we understand the formation of limb deformities? Advances in understanding morphogenesis on the molecular and biochemical level, for the first time, are providing the knowledge base necessary for developmental toxicologists to truly understand the mechanisms by which chemicals disrupt embryogenesis. Clearly, we are still far from having models of normal morphogenesis commonly available in the toolbox of the developmental toxicologist and risk assessor, but one day we may witness a revolutionary change not only in how we evaluate developmental toxicity in animal models but also in how toxicity is extrapolated to the human population.
Basic Elements of Dose-Response Assessment
For the purposes of this review, doseresponse assessment can be viewed as three critical steps: identification of the effect (and related exposure level) of most concern; a characterization of the uncertainty present in the database; and an estimate of the exposure level presumed to be free of risk to the human conceptus. In the first step, data from exposed experimental species, as well as any epidemiological information, is examined for the highest dose level that is without a significant adverse effect. This dose level is established by a combination of statistical analysis and expert opinion and is generally referred to as the NOAEL (the no observed adverse effect level). It is important not to confuse the concept of NOAEL with that of threshold for biological effects, as the former merely reflects the statistical power of an experiment to see an effect when in fact one does exist. Various regulatory agencies have provided guidelines for the design, conduct, and interpretation of such hazard identification studies for developmental toxicity (1) . The lowest NOAEL in the database on a particular chemical is termed the critical NOAEL. In the second step, the adequacy, relevance, and uncertainties in extrapolating the NOAEL from the experimental species to the target species are estimated. Minimally, these extrapolations consider the sensitivity of the human, relative to test species, and the presence of 'potentially sensitive subpopulations. In the default situation, uncertainty factors of 10 are used to cover both sources of uncertainty. Other uncertainty or modifying factors may be applied to account for a lack of identification of a NOAEL, an incomplete database, or an expert opinion regarding the probability of risk. In the final step, the critical NOAEL is divided by the product of the uncertainty factors, as well as any expertderived modifying factors (MF) to obtain the reference dose [RfD] (or reference concentration (RfC) for an inhaled chemical). (1) (2) (3) (4) .
Qualitative and Semiquantitative Approaches
Perhaps the easiest and most straightforward approach to incorporating mechanisms into dose-response assessment occurs when it can be demonstrated that the animal model yields results that are not extrapolatable (a process that can be called qualitative nonextrapolation). While this may be pertinent only on rare occasions, the impact is always profound. Excellent examples of this have been derived by research into the mechanisms of carcinogenesis, where we now understand that saccharin-induced bladder tumors in rodents and t2-microglobulin-induced kidney tumors in male rats have no homologous counterpart in humans. Likewise, if a metabolite is found to be the proximate toxicant and that metabolite is not formed in humans, then the subsequent effect would not be expected to occur either. In developmental toxicity, examples include the effects of Gram-negative antibiotics in rabbits in which the marked effect of the chemical class on the gut microflora causes a nutritional deficiency that secondarily produces effects on the offspring (5) and the effect of diflunisal-induced axial skeletal defects in rabbits that are due to a speciesspecific maternal hemolytic anemia (6) .
Another approach to incorporating biological understanding into the doseresponse and risk assessment activities is to carefully examine the quality, consistency, and adequacy of the database in light of the default assumptions regarding the presumed sensitivity of humans relative to the experimental species and to the existence of susceptible subpopulations. If (8, 9) .
Many of these criticisms have been addressed by application of statistically based dose-response models in the benchmark dose (BMD) approach (10) . In the BMD approach, a particular effect level is chosen and the dose inducing that response is calculated using a statistical model (Figure 1) . The BMD is then defined as the lower 95% confidence interval on that dose level. In principle, the response level is chosen near the low end of the observable range so no extrapolation is necessary (11 Figure 1 . Benchmark dose calculation. In this idealized graph, the experimental data points are depicted by the symbols, the smooth line is the model fit to the data, and the dashed line is the lower confidence limit on dose for a given response level. The BME is shown here as an extra 5% risk, and the BMD is the dose that corresponds to the intersection of the BME and the confidence interval.
data from all experimental doses into use, and the use of the lower confidence interval on the dose estimate for a particular risk allows the experimental variability to enter into the output. BMDs from different end points or different studies would therefore be based on more similar response levels than occurs with the NOAEL.
To evaluate the utility of the BMD to standard developmental toxicity test data, a database of 246 studies was analyzed (12) (13) (14) (15) . These studies used two doseresponse models applicable to any toxicological end point (the quantal Weibull model and the continuous power model), as well as three models (termed the RVR, NCTR, and LOG models) that incorporate aspects specific to developmental toxicity data (e.g., litter-size effects and intralitter correlations). These studies also examined quantal (Q) end points (the presence or absence of litters with at least one dead or malformed implant) and continuous (C) end points (the mean litter incidence of affected implants and fetal weight). BMDs for various added risk levels (1, 5 , and 10%) were estimated from a variety of model formulations (e.g., the presence of a threshold or litter-size parameter). For incidence data, a total of 1,825 end point-specific BMDs and corresponding NOAELs were determined. For fetal weight, comparisons were based on a subset of studies for which individual fetal weight data were available, and only the continuous power model and the LOG model (with the litter size but without the threshold parameter) were used. To calculate a benchmark dose for reductions in fetal weight, it was first necessary to define what level of effect should be used in the assessment. Therefore, in a preliminary analysis, 18 different definitions of reduced fetal weight were considered in establishing the benchmark effect (BME) level that was similar in magnitude, on average, to traditionally determined NOAELs. Six BMEs for reduced fetal weight were used in the full analysis. These included reductions in the mean fetal weight by 5%, 0.5 standard deviations (SD), or 2 standard errors of the mean (SEM); a reduction in mean fetal weight to the 25th percentile of the control mean; and a 5 or 10% increase in incidence of fetuses weighing less than the 5th or 10th percentile, respectively, of the control litter mean. The NOAEL for reduced fetal weight was less than the highest experimental dose level in 85 of the 173 studies in this subset. X2 tests were used to assess goodness of fit while the magnitude of the log-likelihood estimates were used to compare the influence of optional model parameters. BMDs were then compared with traditionally determined NOAELs.
In the database, QNOAELs (the NOAEL for an end point based upon whether a litter contained an affected implant) were similar in magnitude to CNOAELs (the NOAEL for an end point based upon the mean incidence of affected implants within litters). Both generic and developmental-specific models provided acceptable fits to the data from these standard developmental toxicity bioassays. For the generic models, goodness of fit tests were rejected in less than 4% of all analyses. A very low frequency of nonconvergence (4/1,825) occurred, which seemed to coincide with dose-response patterns in which the response at low doses was higher than that at higher dose levels. For the developmental-specific models, incorporation of the litter size but not the threshold parameter marginally improved model fit, and the LOG model was slightly better than the RVR and NCTR models in terms of model fit (probably the result of its more flexible handling of the litter-size parameter).
In nearly every comparison, the median ratios of benchmarks to NOAELs were closer to unity than the means, suggesting the presence of non-normal distributions. In comparisons based upon the quantal approach, the best match on average between NOAELs and the BMDS was found for a QMBDLO (a 10% added risk from the quantal Weibull model). The median benchmark-to-NOAEL ratio at this risk level was 0.5, and 88% of the BMDs were within a factor of 5 of the NOAEL. When comparisons were based upon more continuous measures of response (the mean litter incidence), the best matches were found between the NOAEL and a CBMD05 (a 5% added risk from the continuous power model), and a BMD05 from any of the three developmental-specific models. For example, the median CBMDto-NOAEL ratio was 1.04, and 95% of the benchmarks were within a factor of 5 of the NOAEL; and only 9/486 (1.85%) of the comparisons differed by a factor of 10. All six operational definitions of reduced fetal weight listed above provided BMDs that were similar, on average to the NOAELs. The median benchmark to NOAEL ratios ranged from a low of 0.9 for a BME of a 2 SEM reduction in the average litter mean to a high of 1.24 for a 5% reduction in the average litter mean. In only 9/76 comparisons (11.8%) did any of the BMDs from the six definitions of a BME for reduced fetal weight differ from the NOAEL by more than a factor of 4. The largest such difference was 18-fold. Two aspects, often in combination, generally contributed to the differences of unusual magnitudes between the BMD05 for the reduced fetal weight BMEs and the corresponding NOAELs. The first of these was the use of a study design with wide dose spacing and the second was the presence of a shallow dose-response pattern. In the former instance, a very wide interval between the NOAEL and LOAEL dose would tend to produce NOAELs that might be considered to be artificially low (recall that unlike the benchmark dose, the NOAEL is constrained to be one of the experimental doses). In the latter instance, the shallow slope can make determination of the NOAEL more arbitrary and unstable. Combined, these two aspects can therefore be expected to create greater than normal heterogeneity in the BMD-to-NOAEL ratio. (16) presented a model of the probability of abnormality, which is defined as the probability that an offspring is either dead, malformed, or of low fetal weight. The model can be simply expressed as
where P(d) is the overall probability of being normal at dose d, PI is the probability of death or resorption, and P2 is the probability of malformation or low weight conditional on survival. The models were fit using generalized estimating equations (GEE), which are computationally simpler than maximum likelihood methods and also have relaxed distributional assumptions. The probability of fetal death or resorption was initially modeled as a function of dose using a probit model with a power parameter. Next, outcomes among live fetuses were modeled using a twostage regression approach. The (18) later extended the comparison of binomial and trinomial models to 11 datasets and found that when both end points were affected by dose, the ED05s were always lower for overall toxicity and the standard errors of the estimate tended to be smaller. When only one end point was affected by dose, the ED05 for overall toxicity approximated that for the affected end point.
As seen in both examples of multinomial approaches to developmental toxicity, there is a gain in sensitivity (conservatism) in estimating the joint probability of response when multiple end points are affected by exposure. As many of the measured end points are intercorrelated, and perhaps even related biologically, there seems to be considerable logic in models that are capable of estimating the overall risk of adverse outcome; there are also computational advantages of these models. However, they have not been extensively evaluated in large numbers of datasets, and the gains in precision generally appear to be relatively small.
Study Design Implications of the BMD Approach
The practical consideration of identifying the highest experimental group that does not differ significantly from the control group has led to study designs for developmental toxicology that generally consist of four dose groups (one control and three treated) of 20 litters each. The high dose is usually targeted to induce mild maternal toxicity, with lower doses set either by progressively halving the higher doses or by other factors, such as the desire to ensure that no adverse maternal or developmental effects are observed at the lowest experimental dose. Given the sample sizes and background response rates, these designs are generally capable of detecting a 3-to 6-fold increase in embryonic death, a 5-to 12-fold increase in malformations, and a 15 to 20% decrease in mean fetal weight (1) . With 10-5-106 ) provides a different set of issues related to study design. Thus, it is expected that the BMD will be less sensitive to model misspecification, provided that the models are flexible in terms of handling different dose-response patterns (11) . The most important issue for BMD calculations is how the number of dose groups, their spacing, and sample size affect the precision and accuracy of the risk measure. These aspects were studied by simulating the doseresponse effects of 5-fluorouracil (5-FU) on the incidence of malformations and reduced fetal growth noted in a study by Shuey et al. (19) . The primary findings of that study will be presented in the discussion on biologically based dose models. In the simulation study (20) , fixed sample size designs were studied: a total of 80 A, Box and whisker plot for the dose response for abnormalities derived from 1,000 samplings of the simulated population. The smooth line is drawn through the true population response at each dose level. In the box and whiskers, the box encloses the interquartile range, the lines extending from the box reach the 10th and 90th percentiles, and the line in the box is the median value. Figure 3 , with each submodel linked together by common variables. Conventional dose-response models relate some measure of final outcome, such as incidence of malformations or average weights, directly to an administered dosage. It is more natural for this kind of BBDR to predict time courses of phenomena because it is usually easier to express models in terms of rates. So, for example, a pharmacokinetic submodel will predict the concentration of a compound at the target cell surface for a continuous range of times after dosing; submodels for the interaction with molecular receptors and subsequent changes in cellular behavior will predict the time course of such behaviors (e.g., the fraction of cells undergoing apoptosis at a given time). Lastly, the time course of the final end points in the causal cascade must be related to the observed adverse effect.
Consider as an example a model for the effects of 5-FU on cell-cycle kinetics in the rat fetus described above (19) . A mathematical model is being developed to facilitate the understanding of the relationships among enzyme activities, nucleotide concentrations, and subsequent perturbations of cell kinetics observed in this system. Although the model is still in development (26) (27) (28) , it is far enough along to allow discussion of the salient points in nonmathematical form.
The mathematical model is an attempt to quantify an admittedly simple conceptual model for the developmental toxicity of 5-FU: when pregnant dams are dosed on GD14 by subcutaneous injection, the 5-FU is absorbed from the site of injection into a large, metabolically inactive compartment. From there it enters the blood and is distributed to a metabolically active compartment, which includes renal elimination and the uterus. high-dose observations.
The original motivation for bui this particular model was to account f apparent discrepancy between the reli ship of 5-FU dose to maximum TS ir tion on one hand and that of dose t incidence of malformations and w deficits on the other (19) . In brief, a dosage increases, the marginal incre-TS inhibition decreases sharply. The response for malformations has neo hockey-stick shape ( Figure 2A) ; at the dosages at which malformations begin to increase, the additional increase of TS inhibition due to increases in 5-FU dose has already become very small. The mathematical model reproduces this behavior ( Figure   6 ). Thus, what at first seemed to be evidence for the action of mechanisms other than initially hypothesized is actually the normal behavior of a highly nonlinear interactive system.
The 5-FU model as described here is far from being useful as a quantitative dose-response model for risk assessment; however, it serves as the source of some instructive points. First of all, the model reproduces the very steep increase in malformations seen in rats exposed in vivo beginning at 30 mg/kg in its prediction of cell cycle disruption (Figure 7 ). Although this -ymay yet turn out to be an artifact of model 40 construction, the observation points out the possibility of using such models to infer safe exposure levels based on a quanti- and other persistent environmental chemicals that mimic or inhibit the effect of endogenous hormones may provide examples. Such efforts may also be warranted for chemicals that are being proposed for significantly new uses in which the potential economic gain to the supplier and resulting widespread human exposure justifies extended examination of the hazards identified by more traditional toxicological approaches (e.g., fuel additives, alternative fuels). Perhaps the greatest potential for such models is not for assessments of specific chemicals but as research tools to help elucidate general mechanisms of toxicity. As the experience with such investigations accumulates, it may be that their results could be treated as a toolbox out of which models for new compounds could be constructed with only incremental increases in effort. In the meantime, the rigor required to construct BBDR models can only benefit toxicological mechanistic investigation.
The Embryologically Based Approach
The final approach we present is dearly the most visionary and hypothetical of the approaches. The EBDR approach begins not with an effect and mechanism but with the fundamental understanding of normal morphogenesis and, only secondarily, factors in how these events are perturbed by exogenous agents. Such models would be adaptable to the effects of multiple chemicals provided they captured the salient biological events. The biological understanding of morphogenesis at the molecular level, linked with mathematical theories and constructs of pattern formation, may open the door for these approaches. We will use recent advances in the understanding of the role of homeobox genes in development of the axial skeleton and limbs to illustrate how the emerging knowledge of positional signaling is providing information to take the heretofore theoretical models of pattern formation into potential use by developmental toxicologists.
Homeobox genes, so named for a 183 bp DNA sequence that yields a 61 amino acid protein sequence containing a DNA binding domain, were first described in Drosophila about 10 years ago (34) . These genes are highly conserved across many phyla, and today some 38 Hox genes organized in four chromosome complexes are recognized in the mouse (Figure 8 Haoxd-9 and d-11 (63) ; dimethadione (64) and retinoic acid (65) are but a few examples. Posteriorizations of the thoracolumbar border have also been observed (66) (67) (68) , but this effect is clearly less frequent in the developmental toxicology literature. Toxicant-induced alterations are not limited to the thoraco-lumbar border and may also involve posteriorizations of the cervical-thoraco juncture, as demonstrated by experiments with methanol (69, 70) and boric acid (67) . In general, these agents induce frank dysmorphologies of the axial skeleton at higher dose levels; however, the phenotypes rarely, if ever, completely resemble the null hox phenotypes regardless of response level. Closer examination of subtle skeletal morphological features in developmental toxicity bioassays may strengthen the impact of the effects on the axial skeleton. We see changes at the major boundaries because that is where our attention has been focused and because of the ease of observing such changes. In addition, comparison with phenotypes from individual null mutations might not be expected to produce complete concordance due to other possible pathogenic pathways as well as the-potential redundancy in Hox gene function (52) .
The study of pattern formation in the limb has perhaps received the most attention of any vertebrate organ (71) (72) (73) (74) (75) . The limb begins as an outgrowth of the lateral somatic mesoderm as cell proliferation slows in the regions immediately anterior and posterior to the emerging bud. An apical epidermal ridge (AER) soon develops and is maintained by the underlying mesoderm. In turn, the AER supports proliferation of the underlying mesenchymal cells in what is termed the progress zone (PZ). Recent evidence suggests that fibroblast growth factor (FGF) 2 and FGF 4 may be the morphogenetic signal emanating from the AER. Continued cell proliferation in the PZ gradually establishes the proximaldistal axis of the limb. As shown by surgical removal of the AER at various stages, the longer cells stay in the PZ, the more distal the structures they will form. As cells leave the -PZ, they decrease their rate of proliferation and begin to differentiate; thus as they exit, they are believed to have acquired some aspects of positional identity. A small set of cells in the posterior area of the PZ then gains a special property that contributes to the anterior-posterior axis. This area, known as the zone of polarizing activity (ZPA), was first identified by its ability to induce digit duplications when grafted into the anterior region of the emerging bud (76) . The polarizing ability of the ZPA was at one time thought to be due to its role in establishing a gradient of retinoic acid, but it has now been demonstrated to result from expression of sonic hedgehog (Shh), a gene related to Drosophila segment polarity gene hedgehog (77 This concept has been referred to as positional information (82, 83 Models for developmental processes have been mostly abstract explanations of the consequrences of hypothesized mechanisms of pattern formation. Molecular embyrology, as exemplified by the discussion of the role of Hox genes and other factors in specifying segment identity, is now providing concrete expressions for the hypothesized mechanisms. Thus, models of pattern formation should take on new significance when combined with the detailed understanding of how locational information is actually expressed at the molecular level during development.
Historically, two principal mechanisms have been proposed to convey positional information in the mathematical models. The most common approach uses a gradient of chemicals to provide the positional information. In an interesting recent example, Levin (85) supposes that the products of two genes are initially distributed on a gradient and interact intracellularly to produce complicated patterns, making use of fractals and chaos theory to generate developmental patterns. A more common model relies on pairs of diffusing chemicals that interact with each other to form stable patterns in the concentration of the two chemicals (reaction-diffusion models). In the general form for such a system, one of the chemicals catalyzes its own synthesis as well as that of a second chemical, which inhibits the synthesis of the first chemical. Both chemicals diffuse away from their point of synthesis, but the inhibitor diffuses faster.
Thus, there arises a common developmental pattern of local self-enhancement and long-range inhibition. Simple models, with this structure as a point of departure and with a single spatial dimension as well as time, can demonstrate a number of spatial patterns such as gradients or stripes and can qualitatively reproduce the behavior of some experimental developing systems after they are perturbed (86) .
In the other approach, mechanicochemical models, pattern formation and morphogenesis evolve simultaneously to produce the final pattern. Here a more simple positional signal, for example, a simple gradient in a chemical, interacts with other mechanical aspects of cells, such as differential adhesion and motility, to generate the final pattern. No prepattern is formed in these models; rather, it is the innate behavior of the cells themselves that forms the final morphogenetic pattern. As in reaction-diffusion models, successful mechanico-chemical models generate a pattern of local enhancement and longrange inhibition (87) . Figure 11 shows an example of how a simple model involving chemotaxis and mitosis of pigment cells can reproduce the complicated skin pigmentation patterns seen in snakes (88) . Sometimes, to account for the development of complex patterns, the underlying parameters of the model, such as the size of the developing tissue or organ, are allowed to change (87, 88) . The resulting pattern is an interaction between the stable pattern that would have evolved for fixed parameters and the change in the parameters.
For much mathematical modeling in developmental biology, the general form has been to show that some specific pattern could be generated by a particular mechanism. Often, the absence of much-detailed biological information, such as rates of reaction, actual cellular behavior, and even the identity of hypothetical reacting chemicals, has forced such models to be fairly abstract. Even so, their ability to show the consequences of simple hypotheses of interaction has been valuable, both for testing hypotheses about mechanisms of development and for augmenting biologists' intuition about such systems. However, in risk assessment, we are likely to have fairly detailed and specific information about how a chemical interacts at the subcellular level and how the cells' behavior changes as a consequence. To be able to link these changes to developmental changes, more detailed and specific models for morphogenesis are needed. The problem changes from demonstrating that a particular pattern could be generated by a given mechanism to quantifying how much a particular cellular behavior can change without affecting subsequent morphogenesis or, more generally, how much morphogenesis is affected by a given change in cellular behavior. Naturally, before we can solve this problem, much more needs to be learned about normal development, and more specific models for normal development need to be developed. This is perhaps an area where developmental toxicologists and developmental biologists can collaborate successfully. By using the plethora of developmental perturbations available through developmental toxicants and observing and modeling their effects on normal development, our knowledge of both normal and abnormal development should be greatly enhanced. The emerging knowledge base on molecular morphogenesis as exemplified by the axial skeleton and limbs appears ripe for the task. 
